

Michael R Grunwald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/194954/publications.pdf>

Version: 2024-02-01

67
papers

1,734
citations

361413

20
h-index

302126

39
g-index

70
all docs

70
docs citations

70
times ranked

2502
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. <i>Blood</i> , 2013, 121, 4655-4662.	1.4	355
2	FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. <i>International Journal of Hematology</i> , 2013, 97, 683-694.	1.6	142
3	A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. <i>Blood</i> , 2017, 129, 1143-1154.	1.4	125
4	HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. <i>Blood</i> , 2021, 138, 273-282.	1.4	88
5	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	5.2	71
6	Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1939-1949.	5.2	63
7	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
8	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	1.6	61
9	HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. <i>Blood</i> , 2022, 139, 1452-1468.	1.4	52
10	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20.	1.2	45
11	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 767-775.	2.0	41
12	Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 785-790.	2.0	38
13	FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015, 52, 193-199.	3.4	37
14	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
15	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404.	7.1	32
16	Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1989-1995.	2.0	31
17	Evaluation of <sc>CYP</sc>2C19 Genotypeâ€Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 571-579.	4.7	27
18	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. <i>Blood Advances</i> , 2021, 5, 975-983.	5.2	27

#	ARTICLE	IF	CITATIONS
19	Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. <i>Leukemia</i> , 2022, 36, 856-864.	7.2	26
20	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
21	Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 590-596.	0.4	22
22	Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 656-663.	2.0	20
23	Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 788-795.e2.	0.4	19
24	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
25	Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2019, 134, 3907-3907.	1.4	17
26	Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 579-584.e1.	0.4	16
27	Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy. <i>JCO Oncology Practice</i> , 2022, 18, e1494-e1504.	2.9	16
28	Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 3052-3061.	5.2	15
29	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	1.2	15
30	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	1.2	15
31	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
32	Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. <i>JCO Oncology Practice</i> , 2021, 17, e497-e505.	2.9	14
33	Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 219-225.	0.4	13
34	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
35	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 109.e1-109.e8.	1.2	12
36	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	1.2	11

#	ARTICLE	IF	CITATIONS
37	Patient Reported Financial Toxicity in Acute Leukemia. <i>Blood</i> , 2018, 132, 4796-4796.	1.4	10
38	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.	3.5	10
39	Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. <i>Haematologica</i> , 2022, 107, 1106-1110.	3.5	8
40	Microgranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 35-38.	0.9	7
41	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	1.3	7
42	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
43	Ruxolitinib resistance or intolerance in steroidâ€‘refractory acute graftâ€‘versus â€‘host disease â€‘ a realâ€‘world outcomes analysis. <i>British Journal of Haematology</i> , 2021, 195, 429-432.	2.5	6
44	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 581-586.	2.0	5
45	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i>-rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	5.2	5
46	Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohort Study (REVEAL). <i>Blood</i> , 2019, 134, 168-168.	1.4	5
47	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 993.e1-993.e8.	1.2	4
48	Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib. <i>Blood</i> , 2020, 136, 8-9.	1.4	4
49	Patient Reported Financial Toxicity in Myeloproliferative Neoplasms. <i>Blood</i> , 2019, 134, 2099-2099.	1.4	4
50	A Real-World Evaluation of the Association between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data from the REVEAL Study). <i>Blood</i> , 2021, 138, 239-239.	1.4	4
51	Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience. <i>Blood</i> , 2020, 136, 33-34.	1.4	4
52	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3
53	Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor. <i>Blood</i> , 2019, 134, 3323-3323.	1.4	2
54	Tandem Duplication PCR (TD-PCR) Is a Novel Method of Detecting Minimal Residual Disease in FLT3/ITD AML and Is Highly Predictive of Relapse Risk Following Allogeneic Transplant.. <i>Blood</i> , 2012, 120, 2479-2479.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients. Blood, 2020, 136, 14-15.	1.4	2
56	Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?. International Journal of Hematologic Oncology, 2013, 2, 9-11.	1.6	1
57	Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients. Blood, 2020, 136, 21-21.	1.4	1
58	Allogeneic Hematopoietic Cell Transplantation in Septuagenarians. Biology of Blood and Marrow Transplantation, 2013, 19, 1276-1278.	2.0	0
59	Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplantation Program. Blood, 2016, 128, 3580-3580.	1.4	0
60	Incidence and Risk Factors Associated with Fatal Graft Vs Host Disease after Solid Organ Transplantation in United Network of Organ Transplant Database. Blood, 2021, 138, 4067-4067.	1.4	0
61	Acute Myeloid Leukemia Patients in Complete Remission with Positive Measurable Residual Disease Prior to Allogeneic Transplant Have Worse Outcomes, Similar to Active Disease Regardless of Conditioning Regimen Intensity and Post-Transplant Cyclophosphamide Administration. Blood, 2021, 138, 4907-4907.	1.4	0
62	Clinical Characteristics and Treatment Patterns By Risk Stratification in Patients with Essential Thrombocythemia: An Analysis of the MOST Study. Blood, 2020, 136, 12-13.	1.4	0
63	Specialty Pharmacy and Physician Partnership Optimizes Clinical Pathway Adherence in Myelofibrosis (MF): Initial Analysis of a Quality Improvement Initiative. Blood, 2020, 136, 40-41.	1.4	0
64	Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients. Blood, 2020, 136, 5-6.	1.4	0
65	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Cvhd Prophylaxis Regimens. Blood, 2020, 136, 21-22.	1.4	0
66	Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF). Leukemia and Lymphoma, 2022, , 1-3.	1.3	0
67	Recent advances in hematopoietic cell transplantation in myelodysplastic syndrome. Discovery Medicine, 2017, 24, 51-57.	0.5	0